PRINCETON, N.J. , Sept.
16, 2024 /PRNewswire/ -- Soligenix , Inc. ( Nasdaq : SNGX ) ( Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, is pleased to invite investors to a webinar on September 18, 2024 , at 4:15 p.m .
ET. The exclusive event, hosted by RedChip Companies, Inc., will feature Soligenix President and Chief Executive Officer, Christopher J.
Schaber , PhD, who will share insight into the Company's current development pipeline and upcoming milestones. The Company's pipeline includes several product candidates in advanced clinical stages, targeting a potential $2 billion in annual global sales. Notable among these is HyBryteTM (synthetic hypericin), a photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare chronic cancer, which has demonstrated positive results in a Phase 3 study published in JAMA Dermatology .
The Company is now preparing to initiate a follow-up confirmatory Phase 3 study before yearend and recently reported positive data from a supportive comparability study; HyBryte'sTM market potential is estimated at approximately $250 million . Additional promising assets include SGX302, aimed at treating psoriasis, currently in a Phase 2a trial with a market potential exceeding $1 billion ; and SGX945 for Behçet's Disease, with a Phase 2a study set to begin later this year as well. Soligenix's pipeline also includes a Publ.